Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3569 - Sites of Metastasis and Association with Clinical Outcome (CO) in Advanced Stage Cancer Patients (Pts) Treated with Immunotherapy (IO)


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research



Tumour Site


Mehmet Bilen


Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288


M.A. Bilen1, J.M. Shabto2, D.J. Martini2, Y. Liu3, C. Lewis1, H.H. Collins1, M. Akce1, H. Kissick4, B.C. Carthon1, W.L. Shaib1, O.B. Alese1, C.E. Steuer1, C. Wu1, D.H. Lawson1, R. Kudchadkar1, V. Master4, B. El-Rayes1, S.S. Ramalingam1, T.K. Owonikoko1, R.D. Harvey1

Author affiliations

  • 1 Department Of Hematology And Medical Oncology, Winship Cancer Institute of Emory University, 30322 - Atlanta/US
  • 2 Hematology And Medical Oncology, Emory University School of Medicine, 30307 - Atlanta/US
  • 3 Departments Of Biostatistics And Bioinformatics, Emory University, 30307 - Atlanta/US
  • 4 Department Of Urology, Emory University, 30322 - Atlanta/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3569


Selecting the appropriate pts to receive IO remains a challenge due to the lack of optimal biomarkers. We investigated the association between sites of metastatic disease and CO in pts enrolled on IO-based phase 1 clinical trials.


We conducted a retrospective review of 90 pts treated on IO-based phase 1 clinical trials at Winship Cancer Institute of Emory University between 2009-2017, including sites of metastasis. Overall survival (OS) and progression-free survival (PFS) were measured from the first dose of IO to date of death or clinical or radiographic progression, respectively. Clinical benefit (CB) was defined as a complete response (CR), partial response (PR), or stable disease (SD). Univariate analysis (UVA) and multivariate analysis (MVA) was carried out using Cox proportional hazard model or logistic regression model.


The median age was 63 years and 53% of pts were men. The most common histologies were melanoma (33%) and gastrointestinal cancers (22%). Sites of metastasis were lymph node (N = 58), liver (N = 40), lung (N = 37), bone (N = 24), and brain (N = 8). Most pts (81%) were Royal Marsden Hospital (RMH) good risk. Liver metastases were associated with significantly shorter OS, PFS, and lower rate of CB (Table).Table: 1221P

UVA and MVA of liver metastases with CO

HR (CI)p-valueHR (CI)p-valueHR (CI)p-valueHR (CI)p-valueOR (CI)p-valueOR (CI)p-value
No liver metastases (n = 50)0.42 (0.23-0.78)0.006*0.38 (0.17-0.84)0.017*0.60 (0.39-0.93)0.024*0.73 (0.42-1.26)0.2552.64 (1.11-6.28)0.028*1.09 (0.27-4.44)0.903
Median: 21.9 months 12 month survival: 60%Median: 3.6 months 12 month survival: 13%Rate: 56% (6 PR, 22 SD, 17 PD, 5 NE)
Liver metastases (n = 40)Median: 8.1 months 12 month survival: 19%Median: 1.8 mos 12 month survival: 5%Rate: 33% (1 CR, 1 PR, 11 SD, 24 PD, 3 NE)

Covariates included in MVA were age, whether IO is indicated for the pts histology, ECOG PS, RMH risk group, number of metastatic sites and histology


statistically significant PD: Progressive disease, NE: Not evaluable


Liver metastases are a poor prognostic factor in pts treated on IO-based phase 1 clinical trials. These findings should be validated in a larger study. Equal Contribution: MAB, JMS, DJM.

Clinical trial identification

Legal entity responsible for the study

Emory University IRB.


Research reported in this publication was supported in part by the Biostatistics and Bioinformatics Shared Resource of the Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Editorial Acknowledgement


M.A. Bilen: Consulting/advisory role: Exelixis, Sanofi; Research funding: Bayer, Bristol-Myers Squibb, Genentech/Roche, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Peleton, Pfizer. B.C. Carthon: Consulting/advisory role: Astellas Medivation, Pfizer, Blue Earth Diagnostics; Travel accommodations: Bristol-Myers Squibb. W.L. Shaib: Research funding: ArQule, Lilly. C. Wu: Honorarium: BioTheranostics; Research funding: Amgen, Bristol-Myers Squibb, Vaccinex, Boston Biomedical. R. Kudchadkar: Consulting/advisory role: Bristol-Myers Squibb, Novartis, Array BioPharma; Honorarium: Bristol-Myers Squibb; Research funding: Merck. B. El-Rayes: Consulting/advisory role: Merrimack, BTG, Bayer, Loxo, RTI Health Solutions; Member of the speakers’ bureau: Lexicon, Bristol-Myers Squibb; Honorarium: from Lexicon, RTI Health Solutions, Bayer; Research funding: Taiho Pharmaceutical, Bristol-Myers Squibb, Boston Biomedical, Cleave Biosciences, Genentech, AVEO, Pfizer, Novartis, Hoosier Cancer Research Network, Five Prime Therapeutics, PPD Inc., Merck, ICON Clinical research. S.S. Ramalingam: Consulting/advisory role: Amgen, Boehringer Ingelheim, Celgene, Genetech/Roche, Lilly/ImClone, Bristol-Myers Squibb, AstraZeneca, Abbvie, Merck, Takeda; Travel accommodations: EMD Serono, Pfizer, AstraZeneca. T.K. Owonikoko: Consulting/advisory role: Novartis, Celgene, Lilly, Sandoz, Abbvie, Eisai, G1 Therapeutics, Takeda, Seattle Genetics, Bristol-Myers Squibb, MedImmune; Intellectual property of the following: “Overcoming acquired resistance to chemotherapy treatments through suppression of STAT3” and “Selective chemotherapy treatments and diagnostic methods related thereto”; Research funding: Novartis, Astellas Pharma, Celgene, Bayer, Stem CentRx, Regeneron, AstraZeneca/MedImmune, Abbvie, G1 Therapeutics, and Bristol-Myers Squibb. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.